普蕊斯（上海）医药科技开发股份有限公司股东减持计划期限届满公告详解
一、公告背景与核心内容
普蕊斯（上海）医药科技开发股份有限公司（证券简称：普蕊斯，证券代码：301257）于2026年4月20日发布公告，披露公司股东张晶的股份减持计划已于近期到期并实施完毕。此前，张晶持有公司916,826股，占公司总股本的1.1605%。根据2026年1月14日发布的减持计划，张晶拟在公告披露后3个交易日后的3个月内，通过大宗交易和/或集中竞价方式减持不超过916,826股。
二、减持实施情况及详细数据
- 实际减持股份数量及均价：
- 通过集中竞价方式：2026年2月3日至2月10日，减持32,147股，减持均价72.06元/股。
- 通过大宗交易方式：2026年3月24日至4月16日，减持500,000股，减持均价41.70元/股。
- 累计减持股份：532,147股，占总股本0.6736%。
- 减持前后持股变动：
- 减持前持股：916,826股，占总股本1.1605%。
- 减持后持股：384,679股，占总股本0.4869%。
- 全部为无限售条件流通股，无限售股份未变动。
三、合规性与承诺履行
- 本次减持计划严格按照《证券法》、《上市公司股东减持股份管理暂行办法》、《深圳证券交易所创业板股票上市规则》及相关自律监管指引等法律法规执行。
- 减持计划已提前披露，实际减持数量未超过原计划。
- 张晶已履行其在公司首次公开发行股票及上市时的相关承诺，本次减持不存在违诺行为。
- 张晶不属于公司控股股东、实际控制人，也不是其一致行动人，因此本次减持不会影响公司控制权和治理结构。
四、对投资者的影响及关注要点
- 价格敏感信息：
- 张晶本次减持股份数量较大，且减持价格（尤其大宗交易均价为41.70元/股）显著低于集中竞价均价（72.06元/股）。这可能反映出市场流动性、定价预期或股东个人资金安排，对市场价格产生一定影响。
- 减持后，张晶持股比例降至0.4869%，其对公司影响力进一步下降，未来减持压力相对降低。
- 投资者需关注：
- 减持股份均为无限售条件流通股，市场抛售压力已部分释放。
- 未来如有其他重要股东减持，将继续对股价构成影响，投资者需持续关注公司后续公告。
- 本次减持行为未导致公司控制权变更，不影响公司正常治理与持续经营。
五、备查文件
股东张晶出具的《股份减持计划期限届满的告知函》。
六、总结
本次减持虽未触及公司控制权变动，但由于减持数量及价格差异，属价格敏感信息，或对短期股价产生波动影响，投资者需予以关注。
免责声明：本文基于公司公告及相关文件整理，仅供投资者参考，不构成任何投资建议。投资者据此操作，风险自担。
Detailed Analysis: Prece (Shanghai) Pharmaceutical Technology Shareholder Reduction Plan Expiry Announcement
1. Background and Key Content
Prece (Shanghai) Pharmaceutical Technology Development Co., Ltd. (Stock Code: 301257, Short Name: Prece) announced on April 20, 2026, that the share reduction plan of shareholder Zhang Jing has expired and been completed. Previously, Zhang Jing held 916,826 shares, representing 1.1605% of the company’s total share capital. As per the plan disclosed on January 14, 2026, Zhang Jing intended to reduce up to 916,826 shares within 3 months after 3 trading days post-announcement, via block trades and/or centralized bidding.
2. Details of Share Reduction Implementation
- Actual number of shares reduced and average prices:
- Centralized bidding: From Feb 3 to Feb 10, 2026, 32,147 shares reduced at an average price of 72.06 yuan/share.
- Block trades: From Mar 24 to Apr 16, 2026, 500,000 shares reduced at an average price of 41.70 yuan/share.
- Total shares reduced: 532,147, accounting for 0.6736% of total share capital.
- Shareholding before and after reduction:
- Before reduction: 916,826 shares (1.1605% of total share capital).
- After reduction: 384,679 shares (0.4869%).
- All shares involved are unrestricted circulating shares.
3. Compliance and Commitment Fulfillment
- The share reduction plan strictly follows the “Securities Law”, “Administrative Measures for Shareholdings Reduction of Listed Company Shareholders”, “ChiNext Listing Rules of Shenzhen Stock Exchange”, and other relevant regulations and guidelines.
- The reduction plan was pre-disclosed, and the actual number of shares reduced did not exceed the plan.
- Zhang Jing fulfilled all commitments made at the time of the company’s IPO and listing; there is no violation.
- Zhang Jing is not a controlling shareholder, actual controller, nor their concerted actor. The reduction does not affect company control or governance.
4. Impact and Key Points for Investors
- Price sensitive information:
- The reduction involved a large number of shares, and the block trade price (41.70 yuan/share) was significantly lower than the centralized bidding price (72.06 yuan/share), which may reflect market liquidity, pricing expectations, or personal cash needs. This could impact the stock price.
- After this reduction, Zhang Jing’s shareholding drops to 0.4869%, further lowering her influence and reducing future reduction pressure.
- Investor notes:
- All reduced shares are unrestricted circulating shares; the selling pressure has been partially released.
- Future reductions by other major shareholders may continue to impact the share price; investors should monitor future disclosures.
- This reduction does not trigger a change in control or affect company operations.
5. Reference Documents
Shareholder Zhang Jing’s “Notice of Share Reduction Plan Expiry”.
6. Summary
Although this reduction does not change the company’s control, the quantity and price difference make it price sensitive and could cause short-term stock price fluctuations. Investors should pay attention.
Disclaimer: This article is based on official company announcements and documents, provided for reference only and does not constitute investment advice. Investors operate at their own risk.
View 普蕊斯 Historical chart here
